高级检索
当前位置: 首页 > 详情页

Metastatic potential of lung squamous cell carcinoma associated with HSPC300 through its interaction with WAVE2

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Canc Inst Hosp, State Key Lab Mol Oncol, Peking Union Med Coll, Beijing 100021, Peoples R China [2]Chinese Acad Med Sci, Beijing 100021, Peoples R China [3]Canc Inst Hosp, Dept Etiol & Carcinogenesis, Peking Union Med Coll, Beijing 100021, Peoples R China [4]Inst Canc Res, Ctr Med Oncol, Queen Marys Sch Med & Dent, London EC1M 6BQ, England [5]China Japan Friendship Hosp, Dept Pathol, Beijing 100029, Peoples R China [6]Canc Inst Hosp, Dept Pathol, Peking Union Med Coll, Beijing 100021, Peoples R China
出处:
ISSN:

关键词: HSPC300 Metastatic potential Lung squamous cell carcinoma WAVE2

摘要:
The small protein, HSPC300 (haematopoietic stem/progenitor cell protein 300), is associated with reorganization of actin filaments and cell movement, but its activity has not been reported in human cancer cells. Here, we investigated the association of HSPC300 expression with clinical features of lung squamous cell carcinoma. High levels of HSPC300 protein were detected in 84.1% of turnout samples, and in 30.8% of adjacent morphologically normal tissues. The number of primary tumours with elevated HSPC300 levels was significantly higher in primary tumours with lymph node metastases as opposed to those without, and also in tumours from patients with more advanced disease. HSPC300 modulates the morphology and motility of cells, as siRNA knockdown caused the reorganization of actin filaments, decreased the formation of pseudopodia, and inhibited the migration of a lung cancer cell line. We further showed that HSPC300 interacted with the WAVE2 protein, and HSPC300 silencing resulted in the degradation of WAVE2 in vitro. HSPC300 and WAVE2 were co-expressed in approximately 85.7% of primary tumours with lymph node metastases. We hypothesize that HSPC300 is associated with metastatic potential of lung squamous cell carcinoma through its interaction with WAVE2. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2008]版:
大类 | 2 区 医学
小类 | 2 区 呼吸系统 3 区 肿瘤学
最新[2025]版:
大类 | 2 区 医学
小类 | 3 区 肿瘤学 3 区 呼吸系统
JCR分区:
出版当年[2007]版:
Q1 RESPIRATORY SYSTEM Q2 ONCOLOGY
最新[2023]版:
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2007版] 出版当年五年平均[2003-2007] 出版前一年[2006版] 出版后一年[2008版]

第一作者:
第一作者单位: [1]Canc Inst Hosp, State Key Lab Mol Oncol, Peking Union Med Coll, Beijing 100021, Peoples R China [2]Chinese Acad Med Sci, Beijing 100021, Peoples R China [3]Canc Inst Hosp, Dept Etiol & Carcinogenesis, Peking Union Med Coll, Beijing 100021, Peoples R China
通讯作者:
通讯机构: [1]Canc Inst Hosp, State Key Lab Mol Oncol, Peking Union Med Coll, Beijing 100021, Peoples R China [2]Chinese Acad Med Sci, Beijing 100021, Peoples R China [3]Canc Inst Hosp, Dept Etiol & Carcinogenesis, Peking Union Med Coll, Beijing 100021, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)